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Abstract
Background: The HER2-inhibiting antibody trastuzumab, in combination with chemotherapy,
significantly improves survival of women with resected, HER2-overexpressing breast cancers, but
is associated with toxicities including a risk of cardiomyopathy. Additionally, the beneficial effect of
trastuzumab is expected to decrease once the drug is discontinued. We proposed to address these
concerns by using cancer vaccines to stimulate HER2 intracellular domain (ICD)-specific T cell and
antibody responses.
Methods: Subjects with stage II (≥ 6 +LN), III, or stage IV breast cancerwith > 50% HER2
overexpressing tumor cells who were disease-free after surgery and adjuvant therapy were eligible.
Vaccines consisted of immature, cultured DC (n = 3), mature cultured DC (n = 3), or mature Flt3-
ligand mobilized peripheral blood DC (n = 1) loaded with ICD, or tetanus toxoid, keyhole limpet
hemocyanin or CMV peptide as controls, and were administered intradermally/subcutaneously four
times at 3 week intervals. ICD-specific T cell and antibody responses were measured. Cardiac
function was determined by MUGA or ECHO; long term disease status was obtained from patient
contact.
Results:  All seven patients successfully underwent DC generation and five received all 4
immunizations. There were no toxicities greater than grade 1 or ejection fraction decrements
below normal. Delayed-type hypersensitivity (DTH) reactions at the injection site occurred in 6/7
patients and HER2 specificity was detected by cytokine flow cytometry or ELISPOT in 5 patients.
At more than 5 years of follow-up, 6/7 had detectable anti-ICD antibodies. One patient
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experienced a pulmonary recurrence at 4 years from their study immunizations. This recurrence
was resected and they are without evidence of disease. All patients are alive and disease-free at
4.6–6.7 years of follow-up.
Conclusion: Although this was a small pilot study, the well-tolerated nature of the vaccines, the
lack of cardiac toxicity, significant immunogenicity, and a 100% 4.5-year survival rate suggest that
vaccination with HER2 ICD protein-containing DC is appropriate for further study in this
population.
Trial Registration: ClinicalTrials.gov NCT00005956
Background
HER2 overexpression occurs in 20–30% of breast cancers
and is associated with more aggressive tumors and poorer
overall survival (OS) in those with resected disease [1].
Recently, the benefit of combining the anti-HER2 anti-
body trastuzumab with chemotherapy in reducing the rate
of recurrence mortality of resected, HER2 overexpressing
breast cancer was established [2]. Although the addition
of trastuzumab significantly improved survival in these
studies, it has been associated with toxicities including
cardiac dysfunction and, less frequently, interstitial pneu-
monitis. Furthermore, the effect of trastuzumab is only
expected to persist while it remains at clinically relevant
concentrations. For these reasons, we sought to study the
role of an alternative strategy to target the intracellular
domain (ICD) of HER2 via stimulation of HER2-specific
T cell and antibody responses using cancer vaccines.
More than a dozen phase I and phase II studies have been
conducted in breast cancer patients with cancer vaccines
[3], that have included proteins, peptides, modified
tumor cells, and dendritic cells loaded with breast tumor
antigens. In these studies, HER2 has been demonstrated
to be immunogenic [4-13]. For example, in a study of 31
patients with stage III or IV HER2+ breast cancer who
received 6 monthly vaccinations consisting of a T helper
epitope from HER2 protein plus GM-CSF, 92% of the
patients demonstrated HER2 immunity as measured by T
cell proliferation. Importantly, immunity lasted for at
least 1 year in 38% of responding patients [7]. Recently, a
vaccine consisting of a peptide derived from the extracel-
lular domain of HER2 (E75 peptide (HER2 369–377))
mixed with GM-CSF was administered at various doses
and schedules to patients with resected node positive and
node negative breast cancer. All patients demonstrated in
vivo DTH responses and in vitro immunologic responses
following vaccination. The recurrence rate for the vacci-
nated patients was 5.6% compared to 14.8% for an obser-
vational group of patients at a median of 24 months
[12,13].
To improve upon the immunologic and clinical activity of
HER2-directed vaccines, we chose dendritic cells (DC) as
the platform for delivering HER2 antigen. DC are the most
effective antigen presenting cell for activating CD8+ cyto-
lytic T cells, CD4+ T cell help, and antibody responses
[14]. Furthermore, most cancer vaccines require cross
presentation of the administered antigen by DC [15]. We
therefore hypothesized that vaccines based on DC loaded
with tumor antigens would provide potent antitumor
responses with low toxicity, precise specificity, and a sus-
tained effect (due to immunologic memory). There are
several possible sources of DC for immunotherapy strate-
gies [16]; DC may be generated in vitro from monocytoid
precursors or CD34+ progenitors [17]. DC may also be
found circulating in the peripheral blood and their num-
bers may be markedly enhanced after administration of
Flt3-ligand [18]. Because there is a debate over whether
mature or immature DC are the preferred cell source for
cancer vaccine strategies, we designed our study as a series
of pilot experiments with one group of patients receiving
immature DC, then the next mature DC, and finally, Flt3-
ligand mobilized DC. Because the efficacy of immuno-
therapy may be greatest in the setting of low burden of
tumor when tumor-induced immune suppression is less
likely, we tested DC-based immunization strategies in
women with resected HER2-expressing breast cancer with
a high risk of recurrence. We previously reported prelimi-
nary data for the immunization response in a subset of
these patients [17]. We now report on long-term safety
and survival of the entire group of women who received
DC loaded with HER2 ICD protein fragment as vaccine
therapy for high-risk breast cancer. In addition, we report
on antibody responses detectable after more than 5 years
of follow-up.
Methods
This phase I study was reviewed and approved by the
Duke University Institutional Review Board in accordance
with all federal, state and local requirements. Patients pro-
vided written informed consent prior to receiving any pro-
tocol therapy.
Patients
Patients were eligible if they had invasive (defined as stage
II with at least 6 positive lymph nodes, stage III, orJournal of Translational Medicine 2007, 5:42 http://www.translational-medicine.com/content/5/1/42
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resected stage IV) HER2-overexpressing (2+ or 3+ by
immunohistochemistry (IHC) or FISH amplified) breast
cancer, a group with a historically high (30–50% or
greater) risk of recurrence. In addition to having under-
gone a complete surgical resection, they were to have com-
pleted adjuvant therapy consisting of chemotherapy (±
trastuzumab) and/or radiotherapy at least 4 weeks prior
to study entry, have normal cardiac function, no evidence
of autoimmune disease, and be free of corticosteroids.
Continuation of adjuvant hormonal therapy was permit-
ted.
Dendritic Cell Vaccine
Patients underwent a 2–4 hour leukapheresis in order to
obtain peripheral blood mononuclear cells (PBMCs) for
generation of DC. Three-quarters of the pheresed PBMCs
were utilized for DC and one-quarter was frozen for base-
line immunologic study. The first DC product for each
patient was generated and used fresh and the remainder
were cryopreserved and thawed when needed for subse-
quent immunizations. The DC were generated ex vivo in
one of three ways: The first three patients (Her2-I-01,
Her2-I-02, and Her2-I-03) were immunized with imma-
ture DC generated from their PBMCs with GM-CSF and
IL-4 over seven days, and loaded with the HER2 ICD pro-
tein (500 µg) (generously provided by Corixa, Inc., Seat-
tle, WA). Control immunizations consisted of similarly
prepared DC loaded with tetanus toxoid (TT) 4 Lf and
keyhole limpet hemocyanin (KLH) 200 µg. The next three
patients (DC-ICD-MAT-01, DC-ICD-MAT-02, DC-ICD-
MAT-03) were immunized with DC generated from their
PBMCs with GM-CSF and IL-4, loaded with the ICD of
HER2 protein, the E75 extracellular domain (ECD) pep-
tide, and then matured with CD40-ligand plus IFNγ. Con-
trol immunizations consisted of similarly prepared DC
loaded with keyhole limpet hemocyanin (KLH) 200 µg, or
CMV pp65 peptide 500 µg. The third cohort was to utilize
blood DC mobilized with FLT3-ligand, loaded with ICD
protein overnight and then matured with GM-CSF, CD40-
ligand and IFNγ. Control immunizations consisted of
similarly prepared DC loaded with tetanus toxoid (TT) 4
Lf, keyhole limpet hemocyanin (KLH) 200 µg, and CMV
pp65 peptide 500 µg. A single patient (FL-DC-MAT-01)
received that preparation, because at that point the ICD
protein and FLT3-ligand became unavailable. Conse-
quently, no further patients were enrolled on this trial. A
total of 4 injections were to be given every 3 weeks as a
combination of intradermal (100 microliters) and subcu-
taneous (900 microliters) injections. Patients were fol-
lowed clinically with routine imaging requested
approximately every 3 months to confirm patient-
reported disease status. MUGA scans or echocardiograms
were recommended upon completion of the immuniza-
tions to monitor ejection fraction.
Immunologic analysis
DTH reactions
The clinical method for measuring immunologic immune
responses consisted of measuring the longest diameter of
induration and erythema at the injection site 48 hours
after each immunization (reported as the delayed type
hypersensitivity (DTH) reaction). In addition, prior to
each immunization and at completion of the series of
immunizations, patients received intradermal injections
of 10 mcg of ICD protein or Candida at 1:1000 dilution
(0.1 ml) to assess reactivity to the immunizing antigen
compared with a control. Patients who received DC
loaded with KLH also had DTH testing with 10 mcg KLH.
The maximum diameter of erythema and induration was
measured at 48 hours after the intradermal injection.
ELISpot
Peripheral blood mononuclear cells were analyzed for
immunologic analysis as follows: Immulon-2 96-well flat
bottom plates were coated with 50 µL/well antihuman
interferon-γ (IFN-γ) monoclonal antibody (MoAb;
M700A, Endogen, Perbio Science, HelsingboFrg, Sweden)
in a coating buffer (1:500) and incubated for a minimum
of 2 hours at room temperature or overnight at 4°C. The
coated plates were washed 10 times with phosphate buff-
ered saline (PBS), 0.1% Tween 20, then blocked with fetal
bovine serum (FBS)-containing medium for 30–60 min-
utes at 37°C, 5% CO2. Effector cells were plated in quad-
ruplicate in serial dilutions starting with 2 × 105 cells/well.
Antigen was added to the wells and the plates were incu-
bated for 48–50 hours at 37°C, 5% CO2, and then
washed. Antihuman IFN-γ biotinylated MoAb 50 µL/well
at 1:500 in 1% FBS/PBS was added and incubated at room
temperature for 2 hours or 4°C overnight, and then
washed. Alkaline phosphatase-strepavidin 50 µL/well
(1:200) in 1% FBS/PBS was added and incubated at room
temperature for 2 hours, and then washed. BCIP/NBT (5-
bromo-4-chloro-3'-indolphosphate p-toluidine salt/
nitro-blue tetrazolium chloride) substrate (Vector Labora-
tories, Burlingame, CA) 50 µL/well was added and incu-
bated for 1 hour at room temperature in the dark, and
then rinsed 3 times with deionized water. The membranes
were dried overnight in the dark. Membranes were
removed using sealing tape (Millipore, Bedford, MA) and
were read by Zellnet Consulting, Inc, using the KS ELISA
Automated Reader System with the KS ELISA 4.2 software
(Carl Zeiss, Inc, Thornwood, NY).
Cytokine Flow Cytometry
Intracellular cytokine staining was performed by incubat-
ing 2–4 × 106 PBMCs isolated pre-immunization and post
immunizations for 5 hours at 37°C in the presence of
anti-CD28 and media alone, ICD protein, KLH protein,
and TT (Sigma-Aldrich, St. Louis, MO). Brefeldin A was
added for the last 3 hours of incubation. The stimulatedJournal of Translational Medicine 2007, 5:42 http://www.translational-medicine.com/content/5/1/42
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cells were washed with 1% bovine serum albumen/PBS,
fixed with 1% paraformaldehyde, and permeabilized
using FACS™ Permeabilizing Solution (Becton Dickinson,
San Jose, CA). Permeabilized cells were then stained with
anti-IFN-γ-FITC, anti-CD69-PE, anti-CD8-PerCP, and
anti-CD4-APC for 30 minutes at room temperature. Cells
were gated by forward and side scatter for lymphocytes
and positively for CD8. CD69 is an activation marker. The
percentage of CD69+/IFN-γ+ cells (ie, activated and
cytokine producing) was then determined.
HER2-ICD ELISA
HER2-ICD protein was dissolved in PBS (10 µg/ml). High
binding 96-well ELISA plates (Immulon 4HBX; Thermo-
Labsystems, Franklin, MA) were coated with HER2-ICD
solution (200 µl/well) for overnight at 4°C. After washing
with 0.05% Tween20 in PBS (PBS-T), 200 µl of 1% bovine
serum albumin in PBS was added for blocking of the wells
and incubated for 2 hours at room temperature. Serially
diluted patients' sera (200 µl/well) were added to the
plates and incubated overnight at 4°C. Control serum
from a normal donor was used as a negative control.
Washed with PBS-T, and alkaline phosphatase-conjugated
goat anti-human IgG (MP Biomedicals, Inc.; Aurora,
Ohio) was put to the plates (1:5000 dilution in PBS) and
incubated for 3 hours at 37°C. Unbound conjugate was
removed by washing with PBS-T, and 1 mg/ml solution of
p-nitrophenyl phosphate in Tris buffer (Sigma, St. Louis,
MO) was added to the wells (50 µl/well). Color develop-
ment was stopped by adding 50 µl of 3N NaOH. Absorb-
ance at 405 nm was measured.
Statistical analysis
Results were immunologic analyses were primarily
descriptive. A Kaplan-Meier disease-free survival estimate
and 95% confidence bounds was generated for the clinical
data.
Results
Patient Characteristics
Seven women with a median age of 47 were enrolled onto
the study (Table 1). Five patients had stage III and two had
stage IV breast cancer. The median number of positive
lymph nodes was 7 (range: 0–11). HER2 expression by
IHC was high in all patients; specifically, 100% of the
tumor cells in two patients, 80% in one patient, and all
others were reported by the pathologist to be ≥ 2+. Two
patients had ER/PR negative tumors. Prior therapy
included high-dose chemotherapy with peripheral blood
stem cell transplantation, hormonal therapy, chemother-
apy, and post-surgical radiotherapy, and in one case, a
dendritic cell vaccine loaded with CEA mRNA. Two
patients had received trastuzumab, one for 12 weeks and
the other for 1 year prior to enrollment. Three of the
women were receiving maintenance hormonal therapy.
All patients successfully underwent leukapheresis and
generation of at least one DC product. Viability of cryop-
reserved DC was 70–98%. The immature DC had the
expected phenotype (CD83 low, CD86+HLA-DR+) and
the matured DC expressed upregulated CD83 (range: 16–
98% CD83+) among both fresh and cryopreserved DC.
The matured DC preparations demonstrated IL-12 pro-
duction. Specifically, within the DC of three patients ana-
lyzed (two in the cohort with monocyte derived and
matured DC and the patient receiving Flt3-ligand mobi-
lized and matured DC), intracellular IL-12 expression was
demonstrated in 2–8% of the CD83+ cells, indicating an
activated state.
Immune Response
We used as the primary indicator of immune response
DTH reactions observed at the vaccine injection sites
(Table 2). These DTH reactions to the ICD loaded vaccine
(erythema and/or induration), ranging from no reaction
up to105 mm in longest diameter, were observed at the
injection site in all but the one patient who received only
a single immunization with the DC. In four patients, the
diameter of the induration/erythema increased from the
first to a subsequent immunization, and in two patients
the first immunization gave the greatest induration/ery-
thema. We also examined reactivity to the antigens
administered intradermally without dendritic cells before
and after all immunizations. Among five patients who
were analyzed, two had an increase in size in the diameter
of erythema/induration at the intradermal injection site
following the immunizations, one had a decrease in size,
and two patients had no DTH reactivity to ICD. When
responses to Candida were similarly analyzed, only one of
five had an increase in the diameter of the DTH reaction,
while four patients had a decrease following all the immu-
nizations. This suggests that responses against the HER2
were likely specific and not due to a non-specific increase
in DTH reactivity.
As further confirmation of the HER2 specificity of the
immune response, we analyzed patient PBMC by ELISpot
and intracellular cytokine staining. ELISpot analysis was
performed on the PBMCs from each patient prior to vac-
cinations (pre), following vaccinations (post), and at long
term follow up (up to 5 years following immunizations)
(Table 2). We initially reported our results in three
patients for immune response during the immunizations
[19]. We now report results for all patients with longer fol-
low-up (up to 5 years). As demonstrated in Table 2, 3 of 3
patients receiving immature DC, and 2 of 3 receiving
matured DC developed a positive or increased response to
ICD protein as demonstrated by ELISpot results. Out of
these 5 patients, 3 had an immune response to Her2-ICD
up to 5 years following the DC vaccinations. Interestingly,
these results indicate the Her2-ICD specific T cell responseJournal of Translational Medicine 2007, 5:42 http://www.translational-medicine.com/content/5/1/42
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was not always greatest at the conclusion of the immuni-
zations. Her2-I-01 and DC-ICD-MAT-03 also had Her2-
ECD specific responses up to 5 years following immuniza-
tions. The patient receiving FLT3-Ligand mobilized and
matured DC did not activate ICD-specific T cells but had
in increase in ECD specific T cells. In patient Her2-I-01, we
confirmed that the Her2-ICD immune response occurred
among both CD4 and CD8+ T cells by intracellular IFNγ
production (Figure 1).
Although T cell responses were the initial primary
immune response measured, when the subjects were eval-
uated at more than 5 years of follow-up, we analyzed anti-
body responses specific for ICD by ELISA. As
Table 2: Longest DTH diameter at injection site of DC loaded with various antigens
Patient Longest 
diameter of 
induration 
at site of DC 
loaded with 
ICD (mm)
Longest 
diameter of 
erythema at 
site of DC 
loaded with 
ICD (mm)
Longest 
diameter of 
induration 
at site of DC 
loaded with 
TT (mm)
Longest 
diameter of 
erythema at 
site of DC 
loaded with 
TT (mm)
Longest 
diameter of 
induration 
at site of DC 
loaded with 
CMV (mm)
Longest 
diameter of 
erythema at 
site of DC 
loaded with 
CMV (mm)
Longest 
diameter of 
induration 
at site of DC 
loaded with 
KLH (mm)
Longest 
diameter of 
erythema at 
site of DC 
loaded with 
KLH (mm)
#1 63 mm 64 mm 39 mm 50 mm NA NA 6 mm 18 mm
#2 35 mm 36 mm 20 mm 25 mm NA NA 20 mm 30 mm
#3 65 mm 105 mm 70 mm 70 mm NA NA 55 mm 135 mm
#4 25 mm 80 mm 45 mm 90 mm 30 mm 80 mm 65 mm 120 mm
#5 20 mm 30 mm NA NA NR 20 mm NR 10 mm
#6 20 mm 40 mm NA NA 10 mm 20 mm 10 mm 20 mm
#7 NR NR NA NA NR NR NR NR
NR = No reaction at the injection site
NA = Not available (i.e., immunization not performed with the antigen listed)
Table 1: Patient characteristics (n = 7)
Patient Age Disease Stage Number + Lymph Nodes HER2 Status Prior Treatment/s Maintenance Hormones
Vaccinations: immature DC (GM-CSF, IL-4) + HER2 ICD protein control DC loaded with KLH and tetanus toxoid
#1 38 T3pN3 – IIIC > 10 > 80% cells 
overexpress by IHC
AC-Taxol; trastuzumab Raloxifene (ER/PR+)
#2 56 T1cpN2M1 – IV 7 100% cells 
overexpress by IHC
Taxol; HDC + Auto 
PBSCT DC-CEA vaccine
Tamoxifen (ER/PR+)
#3 57 T3pN2 – IIIC 7 3+ doxorubicin HDC + Auto 
PBSCT
None (ER/PR-)
Vaccinations: Mature DC (GM-CSF, IL-4, CD40-ligand, IFNγ) + HER2 ICD protein, E75 ECD peptide control DC loaded with KLH 
and CMV peptide
#4 47 T1pN2 – IIIA 8 3+ AC; Taxotere; 
Radiotherapy
None (ER/PR-)
#5 58 T2pN3 – IIIC 11 2+ FAC; Taxol; XRT Tamoxifen (ER/PR+)
#6 38 IV (liver) 0 High Taxotere; Trastuzumab 
(prior to enrollment and 
then continued on 
maintenance > 4 years); 
FAC; Navelbine; RFA of 
liver lesion
None (ER/PR-)
Vaccinations: DC (FLT3-ligand) + GM-CSF + CD40-ligand + IFNγ+ HER2 ICD protein control DC loaded with KLH, tetanus toxoid 
and CMV peptide
#7 45 T4N1 vs N0M0 – 
IIIB
0 @ surgery 3+ in 100% cells by 
IHC
Neoadj AC; post-op 
Taxol; post-mastect RT
None (ER/PR-)
F = Fluorouracil, A = doxorubicin, cyclophosphamide; HDC + PBSC = high dose chemotherapy followed by peripheral blood stem cell transplant; RFA 
= radiofrequency ablation;
IHC = immunohistochemistry
Note: Different IHC methodologies were used by pathologists in characterizing HER2 expression during the time patients were enrolled in the study. 
FISH was not utilized.Journal of Translational Medicine 2007, 5:42 http://www.translational-medicine.com/content/5/1/42
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demonstrated in figure 2, five of 6 evaluable patients had
detectable antibody responses against the ICD with titers
exceeding 1:200. There was no obvious correlation with
the T cell responses, although it is of interest that the
patient who received the Flt3-Ligand mobilized DC devel-
oped the highest titer of anti-ICD antibody response, but
had minimal detectable T cell secretion of interferon-
gamma, suggesting a possible skewing of the T cell reper-
toire to a Th2 response.
Clinical Observations
No acute toxicities were noted during or following any of
the four injections. No patient demonstrated an autoim-
mune response, and no cardiotoxicity, defined as
decreased ejection fraction below normal(< 50% at our
institution or decrease of > 10% from their baseline), was
observed on repeat MUGA scans or echocardiograms
among the six patients for whom follow-up evaluations
were available. In the remaining patient no cardiac events
have been reported, and the patient remains fully func-
tional and active. The only patient-reported toxicities were
related to prior chemotherapy and/or surgery (e.g., neu-
ropathy and lymphedema, respectively).
Only one of seven patients experienced disease recur-
rence; she developed a single HER2+ pulmonary lesion
nearly 4 years after completing all immunizations and is
currently disease-free 9 months post-resection and chem-
otherapy (Figure 3). With a median follow-up of 5.2 years
(range:4.6–6.7 years), the DFS rate is 86% and the overall
survival is 100%. The 95% exact binomial confidence
interval for survival at 4.5 years post-immunization is
(59%, 100%).
Discussion
Patients with resectable, HER2-expressing breast cancer
have a substantial (30% to > 50%) risk for recurrence with
conventional therapy. Recently, a combined analysis of
Antibody response to HER2-ICD protein detected by ELISA Figure 2
Antibody response to HER2-ICD protein detected by 
ELISA. High binding 96-well microtiter plates were coated 
with HER2-ICD protein (10 µg/ml, 200 µl/well) for overnight 
at 4°C. After washing, and blocking with 1% BSA in PBS for 2 
hours, serially diluted patients' sera (200 µl/well) were added 
to the wells in triplicate and incubated overnight at 4°C. 
Control serum from a normal donor was used as a negative 
control. Alkaline phosphatase conjugated anti-human IgG was 
added to the plate after washing, and color was developed 
using p-nitrophenyl phosphate. Absorbance at 405 nm was 
measured and the differences from the control serum at each 
dilution was plotted. The data represents the mean absorb-
ance for each serum dilution ± standard deviation for each 
patient depicted.
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Intracellular IFNγ production in CD4+ and CD8+ cells in  response to HER2-ICD Figure 1
Intracellular IFNγ production in CD4+ and CD8+ 
cells in response to HER2-ICD. PBMC from patient 
Her2-I-01 were stimulated with HER2-ICD (50 µg/ml), KLH 
(50 µg/ml), Tetanus toxoid (5 Lf/ml) or media alone and ana-
lyzed for intracellular IFNγ at weeks 0, 1, 3, 6, and 10. Stimu-
lated cells were fixed, permeabilized and stained with αIFNγ-
FITC, αCD69-PE, αCD8-PerCP and αCD4-APC. The per-
cent of CD4+ and CD8+ T cells that are IFNγ and CD69 
double positive are represented for each antigen. Cells were 
gated by forward and side scatter for lymphocytes and posi-
tively for CD8 or CD4. Arrows represent when the patient 
was given each vaccination: week 0, 3, 6 and 9. The x-axis 
represents week of analysis and y-axis represents percent 
CD4+ or CD8+ cells that are CD69+IFNγ+ in response to 
each antigen.
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1672 HER2+ patients who were treated with doxorubicin,
cyclophosphamide and paclitaxel plus one year of trastu-
zumab demonstrated a 52% reduction in the unadjusted
risk for disease recurrence and a 33% reduction in the
unadjusted risk for mortality compared to those who did
not receive trastuzumab. Four-year disease-free survival
(DFS) and OS rates were 85.3% and 91%, respectively [2].
This required a year of therapy, and as a passive approach,
it only provides activity while the drug persists. We
hypothesized that a cancer vaccine strategy would provide
prolonged efficacy due to T cell immunity, and this report
describes the high rate of long term DFS of seven patients
with high-risk, resected, HER2 overexpressing breast can-
cer after immunization with dendritic cell based vaccines
loaded with the ICD protein.
Our study is noteworthy for several reasons. First, we were
able to generate DCs from PBMCs in all patients despite
significant prior chemotherapy. This demonstrates the
feasibility of this approach in the post-surgery/post-chem-
otherapy setting. Notwithstanding, two patients in the
group who received matured DCs did not receive all 4
immunizations because the manipulations required to
mature and load the DCs with antigen produced signifi-
cant effects on the number and viability of cells. Three dif-
ferent DC-based preparations were utilized among the
seven patients because we were intending to test each for
safety in a pilot fashion as we continued to develop more
convenient and effective DC vaccines. We realize that the
number of different preparations and prior therapies of
the patients may limit the ability to make conclusions, but
nonetheless, all the patients did have in common immu-
nization with ICD and ECD and prolonged relapse-free
survival and 6 of the 7 patients showed development of
HER2 specific immune responses. Unfortunately, our
ability to continue the study was ultimately limited by the
unavailability of clinical grade ICD protein and FLT3-Lig-
and. The generation of protein-based vaccines is compli-
cated by the complexity of producing stable proteins.
Furthermore, there was no evidence that the manipula-
tions required to mature the DC resulted in greater immu-
nogenicity. Neither did the Flt3-ligand mobilized DC
approach seem to improve the T cell responses against the
Table 3: Patient ELISpot response
Patient Antigen Pre Post Follow up 1 Follow up 2
Her2-I-01 ICD - - + (150) + (23)
ECD - + (23) + (114) + (24)
Her2-I-02 ICD - + (22) - N/A
ECD - N/A - N/A
Her2-I-03 ICD - - - + (23)
ECD + (49) - - + (23)
DC-ICD-MAT-01 ICD - + (18) N/A -
ECD - - N/A -
DC-ICD-MAT-02 I C D N / A ---
ECD N/A - - -
DC-ICD-MAT-03 ICD - N/A N/A + (77)
ECD - N/A N/A + (129)
FL-DC-MAT-01 I C D ----
ECD + (46) - - + (84)
A positive ELISpot result is represented by + and the number of spots per 100,000 PBMC in parentheses. A positive (+) result is defined as the 
number of cells secreting IFNγ in response to HERr2-ICD or ECD that is at least 10 more than the number of cells secreting IFNγ in response to 
media alone (control cells) and which is statistically greater than the control cells with p < 0.05.
Each antigen was tested in replicates of 6 for each time point.
Pre represents ELISpot results prior to vaccination, post represents results during or following the vaccination series, and the follow up timepoints 
represent up to 5 years following the study.
Kaplan-Meier Disease-Free Survival Estimate and 95% confi- dence bounds (n = 7) Figure 3
Kaplan-Meier Disease-Free Survival Estimate and 95% confi-
dence bounds (n = 7).
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ICD protein, although it was associated with the highest
antibody titer at 5 years of follow-up. Similarly, Disis and
colleagues [8] reported that Flt3-Ligand did not activate a
HER2-specific proliferative response, although they could
detect Her2-specific T cells responses by ELISPOT. In
order to improve upon the immunogenicity of the vac-
cines used in the current study, we have other strategies in
development including heterologous prime-boost strate-
gies using viral vectors and DC-based vaccines modified
with viral vectors encoding HER2.
Second, we observed vaccine specific immune responses
by DTH in six of seven patients with HER2 ICD protein
administered with an ex vivo generated DC. We confirmed
that these were HER2 ICD-specific T cell responses in five
(two in the mature DC group and three in the immature
DC group) of seven immunized patients. At more than 5
years of follow-up, ICD and ECD-specific immune
responses were detected by ELISPOT and in some cases,
the results were higher than during the immunizations
providing tantalizing evidence that the peak response may
occur significantly after concluding vaccine therapy. Sim-
ilar observations have been made in other HER2 vaccine
studies. Disis and colleagues demonstrated anti-HER2, T-
cell immunity persisting for at least 1 year among 38% of
patients responding to a vaccine derived from potential T-
helper epitopes of the HER2/neu protein admixed with
granulocyte-macrophage colony-stimulating factor (GM-
CSF) [7]. In another study by the same group, over half of
patients (n = 29) enrolled in a dose-escalation study
retained HER2/neu  specific T-cell immunity after treat-
ment with HER2ICD protein plus GM-CSF vaccine 9 to 12
months after immunization had ended [11]. Interestingly,
the rate of immune response seemed to decrease slightly
with increasing dose of vaccine (100% for low dose, 90%
for intermediate dose, and 78% for high dose). In some
cases, there was a rebound of the T cell response 2–3
months (or later) after the immunizations were com-
pleted. Although efficacy was not reported in this phase I
trial, patients with stage II, III and IV HER2 overexpressing
breast cancer were enrolled. Also, although we did not
have serum remaining from prior to immunization to
detect antibody responses, we were encouraged to find
detectable antibody responses specific for the ICD protein
in 5 of 6 patients at 5 years of follow-up. Although existent
antibody responses against HER2 have been detected in
non-immunized patients [20,21], the fact that the Ab
response was against the intracellular domain (ICD) sug-
gests that this response could have been activated by the
vaccine.
Third, although the number of patients was limited by the
eventual unavailability of the ICD protein and FLT3-Lig-
and, the fact that all seven (100%) are alive and currently
disease-free for up to 6 years following the final vaccina-
tion is noteworthy in our opinion. Disis [11] does not
report the percentage of patients alive and disease free, but
does mention that 2/29 patients relapsed before complet-
ing the vaccine series (all were in the low dose cohort).
Although two of our patients had also received trastuzu-
mab, one had received it for only 12 weeks; the other has
continued on trastuzumab for more than 4 years after
completing the immunizations. We are aware that some
patients received adjuvant hormonal therapy which could
have influenced relapse as well. Larger cohorts of patients
must be studied to confirm these results.
Fourth, the immunizations were well tolerated with only
grade 1 toxicities reported. Cardiotoxicity due to the
immunizations was not reported, despite the fact that two
patients had also received trastuzumab and the majority
had received prior anthracyclines.
Conclusion
In this small pilot study, we observed that DC vaccines
loaded with HER2 ICD protein are well tolerated, induce
DTH, T cell, and antibody responses, and are associated
with long term-disease-free survival. It is noteworthy to
compare these results with another HER2 directed therapy
in which the concept of prolonged immunity and its
application to the adjuvant treatment setting was recently
explored in patients with resected node positive and node
negative breast cancer [13]. A vaccine consisting of a pep-
tide derived from the extracellular domain of HER2 (E75
peptide (HER2 369–377)) mixed with GM-CSF was
administered at various doses and schedules. All patients
demonstrated in vivo DTH responses and in vitro immu-
nologic responses following vaccination. The recurrence
rate for the vaccinated patients was 5.6% compared to
14.8% for an observational group of patients at a median
of 24 months. These observations are promising and sup-
port further study of anti-HER2 vaccine therapy after adju-
vant treatment of high-risk, HER2 overexpressing breast
cancer. Because trastuzumab is now a standard treatment
administered to women with HER2 overexpressing breast
cancer as part of adjuvant therapy, and because the safety
of trastuzumab plus HER2 targeting vaccines has been
preliminarily demonstrated [22], future studies will assess
the combination of DC-based HER2 targeting vaccines
with trastuzumab.
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